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Abstract 
Background: Seasonal malaria chemoprevention (SMC) consists of administration of sulfadoxine-pyrimethamine 
(SP) + amodiaquine (AQ) at monthly intervals to children during the malaria transmission period. Whether the addi-
tion of azithromycin (AZ) to SMC could potentiate the benefit of the intervention was tested through a double-blind, 
randomized, placebo-controlled trial. The effect of SMC and the addition of AZ, on malaria transmission and on the life 
history traits of Anopheles gambiae mosquitoes have been investigated.
Methods: The study included 438 children randomly selected from among participants in the SMC + AZ trial and 
198 children from the same area who did not receive chemoprevention. For each participant in the SMC + AZ trial, 
blood was collected 14 to 21 days post treatment, examined for the presence of malaria sexual and asexual stages 
and provided as a blood meal to An. gambiae females using a direct membrane-feeding assay.
Results: The SMC treatment, with or without AZ, significantly reduced the prevalence of asexual Plasmodium falci-
parum (LRT  X22 = 69, P < 0.0001) and the gametocyte prevalence (LRT  X22 = 54, P < 0.0001). In addition, the propor-
tion of infectious feeds (LRT  X22 = 61, P < 0.0001) and the prevalence of oocysts among exposed mosquitoes (LRT 
X22 = 22.8, P < 0.001) was reduced when mosquitoes were fed on blood from treated children compared to untreated 
controls. The addition of AZ to SPAQ was associated with an increased proportion of infectious feeds (LRT  X21 = 5.2, 
P = 0.02), suggesting a significant effect of AZ on gametocyte infectivity. There was a slight negative effect of SPAQ 
and SPAQ + AZ on mosquito survival compared to mosquitoes fed with blood from control children  (LRTX22 = 330, 
P < 0.0001).
Conclusion: This study demonstrates that SMC may contribute to a reduction in human to mosquito transmission of 
P. falciparum, and the reduced mosquito longevity observed for females fed on treated blood may increase the ben-
efit of this intervention in control of malaria. The addition of AZ to SPAQ in SMC appeared to enhance the infectivity of 
gametocytes providing further evidence that this combination is not an appropriate intervention.
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Background
Malaria remains a major cause of morbidity and mortal-
ity, particularly in Africa where 94% of cases occur. Effec-
tive management of clinical cases associated with the use 
of insecticide-impregnated material has been effective 
in reducing malaria transmission and has greatly con-
tributed to the progresses in the fight against the disease 
since the beginning of the century. However, the reduc-
tion of malaria burden has stalled, or even reversed, in 
some countries in the recent years and additional strat-
egies are needed. These include chemopreventive strat-
egies such as intermittent preventive treatment during 
pregnancy (IPTp) and seasonal malaria chemopreven-
tion (SMC) for children [1]. SMC consists of administra-
tion of therapeutic doses of sulfadoxine-pyrimethamine 
(SP) + amodiaquine (AQ) at monthly intervals to children 
aged 3–59  months during the peak malaria transmis-
sion period in areas where malaria transmission is sea-
sonal [2]. In 2019, 21.5 million children in 13 countries 
in Africa’s Sahel and sub-Sahel sub-region received 
malaria prophylaxis through SMC programmes [1]. SMC 
proved to be safe and cost-effective when deployed at 
the population level [3]. Other advantages of SMC are 
that it relies on frequent interactions between health 
staff or training volunteers and young children, which 
provides an opportunity for further benefits for popula-
tions, such as preventive administration of other drugs 
[4]. Mass administration of azithromycin (AZ) has been 
reported to provide a reduction in all cause mortality [5, 
6]. Therefore, to determine whether the addition of AZ 
to SMC could reduce child mortality and morbidity was 
tested through a double-blind, randomized, placebo-
controlled trial in young children in Burkina Faso and 
Mali. This trial showed that the addition of AZ reduced 
the incidence of several infectious diseases but did not 
reduce the incidence of deaths or hospital admissions [4]. 
Addition of AZ to SMC had little effect on the incidence 
of clinical attacks of malaria, but it may have had some 
effect on malaria transmission, and determining whether 
this was the case warrants further attention.
The transmission of malaria parasites from human to 
mosquito vector requires the presence of mature Plas-
modium gametocytes in the ingested blood and both 
host and parasite factors can influence the production 
of gametocytes and their infectivity to mosquitoes [7, 
8]. A large panel of drugs, including anti-malarial mol-
ecules, show positive or negative influence on gametocy-
togenesis, on gametocyte infectivity, and/or on parasite 
development in the mosquito [9–11] and SMC, with or 
without additional drugs, is therefore expected to have an 
effect on human to mosquito transmission.
SP, and AQ to a lesser extent, have been shown to 
enhance the number of gametocytes circulating in the 
peripheral blood [12–14], possibly due to the release of 
sequestered parasites or through natural periodicity of 
parasite development [15]. However, the infectivity of 
gametocytes following SP treatment was low [16, 17]. 
In addition, SP has been shown to have a deleterious 
effect on mosquito survival [17], reflecting the complex 
effects of drug administration on malaria transmission. 
Mass administration of antibiotics to humans may affect 
the mosquito microbiota and possibly influence malaria 
parasite transmission in this way. Indeed, gut-inhabit-
ing bacteria have been shown to interfere with parasite 
transmission in the mosquito and to modulate vector 
competence [18–24]. For instance, the presence of Enter-
obacteriaceae, such as Serratia marcescens, reduced 
the prevalence and intensity of infection [20] or even 
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conferred refractoriness [20, 21, 24–26]. Experimental 
administration of antibiotics to mosquitoes either facili-
tated or impeded their infection, which suggested that 
antibiotics circulating in the blood of human hosts may 
impact the susceptibility of blood-sucking Anopheles 
gambiae females to transmit malaria infection by disturb-
ing their gut microbiota [27]. Moreover, other parameters 
influencing vector capacity, such as mosquito lifespan 
and fecundity, are also affected by ingestion of antibiot-
ics [28]. AZ reduced the Plasmodium falciparum game-
tocyte exflagellation process [29] and negatively affected 
the P. falciparum infection load as well as the mosquito 
lifespan [28] suggesting a potential for AZ to reducing 
malaria transmission.
The present study aimed at evaluating the effect of 
SMC with or without the addition of AZ on malaria 
transmission. It relied on a clinical trial that evaluated 
the benefit of adding AZ to SPAQ [4] and assessed the 
effect of SPAQ and SPAQ + AZ on the transmissibility of 




The study was conducted in Houndé health district, 
located about 100  km from Bobo-Dioulasso along the 
paved road to Ouagadougou, Burkina Faso. In this area, 
the rainy season lasts approximately six months from 
May to October. The main malaria vectors are reported 
to be Anopheles gambiae, Anopheles coluzzii [30]; Anoph-
eles arabiensis is a secondary vector in the area [31]. 
Plasmodium falciparum is the most prevalent malaria 
parasite [32].
Child mortality caused by malaria remains high in 
Houndé in 2013 (36–40%) [33]. Malaria transmission 
occurs during and shortly after the rainy season. Treat-
ment based on artemisinin combination therapy (ACT) 
and bed-net coverage are major malaria control inter-
ventions prior to the study. SMC or mass administration 
of AZ was not deployed at this site prior the study, but 
now the site areas receive SMC provided by the national 
malaria control programmes [4].
In the SMC + AZ trial, the percentage of children who 
received at least three directly observed cycles of the 
assigned regimen was 86.8 and 84.3%, respectively in 
2015 and 2016 [4].
The population was estimated at 329,162 inhabitants in 
the Houndé health district in 2019 and is divided into vil-
lages over an area of 5622 sq km [34, 35]. Four villages: 
Koumbia, Dougmato, Kari and Boni, among the sites 
included in the SMC + AZ trial were selected randomly 
for this study.
Four month, each year, during the peak malaria trans-
mission, study participants received SMC during 3 days. 
In addition, they received AZ or matching AZ placebo. 
All treatment doses were based on age and adminis-
tered by study staff. The village of Pè in the district of 
Houndé, where SMC was not yet in place, was selected 
as a control.
Study participants
The study participants were age 24–59  months at the 
start of the study. For ethical consideration, subjects 
aged 3–24  months from whom venous blood collection 
may often present difficulties did not select. Sample size 
was estimated on the basis of calculations for compar-
ing SMC alone versus SMC + AZ, and SMC versus no 
SMC. Based on the weekly survey during the first year of 
the study, assuming that with SMC to have about 5% of 
mosquitoes infected, and in control children, about 15% 
or more of mosquitoes infected; if AZ reduces mosquito 
infectivity by 50%, to have 80% power to detect a differ-
ence, in total at least 20 to 30 children in each group, with 
50 mosquitoes fed on each child would be needed.
In the four treated villages involved in the SMC + AZ 
trial [4], 438 participants were randomly selected from 
among the 21,737 participants for inclusion in the 
transmission study. The inclusion criteria were age 
24–59 months and parental or other legal guardian con-
sent. Exclusion criteria were chronic illness, symptomatic 
malaria, planned long-term absence from the village dur-
ing the study period, or absence at the moment of inclu-
sion, difficulty in collecting venous blood, or retraction 
of consent. In the control group village of Pê, 198 par-
ticipants were selected according to the same inclusion/
exclusion enrolment criteria used in the villages where 
chemoprevention was provided. Information about the 
trial recruitment was provided during meetings held in 
the medical centre. Ethical approval for the study was 
obtained from the national ethic committee of Burkina 
Faso under the Registration No. 2015-5-56.
Treatment
For the participants who were part of the SMC + AZ trial, 
anti-malarials were administered by trial staff monthly 
between August and November according to the agenda 
of the trial and to be in the line with the annual peak of 
malaria transmission season [4].
Children received 500 mg of SP and 25 mg of pyrimeth-
amine plus 150 mg of AQ on day 1 and 150 mg of AQ on 
days 2 and 3 (Guilin Pharmaceutical, Shanghai, China). 
In addition, they were assigned to receive either 200 mg 
of AZ or matching placebo on days 1, 2, and 3 (Cipla, 
Mumbai, India) through double-blinded administration 
by trial staff [4]. In the village Pê, children did not receive 
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prophylactic anti-malarials. For all participants, an 
artemether–lumefantrine treatment was provided when 
malaria was diagnosed.
Blood collection
At the end of each of the eight rounds of drug adminis-
tration sessions (four sessions per year for two years) and 
in each of the four villages included in the SMC + AZ 
trial, 12 to 18 children were randomly selected for blood 
collection between 14 and 21 days after the start of the 
administration of prophylactic drugs. Evaluating the 
effect of chemoprophylaxis on man-to-mosquito trans-
mission in the time frame of two to three weeks after the 
treatment, while children receive a treatment every four 
weeks, is a reflection of the effect of drug administration 
over the whole treatment season. In parallel to the eight 
treatment sessions, at least 25 untreated children of the 
control village were randomly selected from census list. 
For each selected child, 3  ml of blood were collected 
into a heparinized tube and kept at 37 ℃ in an incubator 
(ENKAB MODEL 70) for transportation to the labora-
tory in Bobo Dioulasso for 2–3 h before mosquito feed-
ing. On arrival in the laboratory, thick blood smears were 
realized using 5 µl of blood.
Microscopy
Thick blood smears were stained with Giemsa (Quimica 
Clinica Aplicada 990939) and independently examined 
by three experienced microscopists. Gametocytaemia 
was based on a count of the number of gametocytes per 
1000 leukocytes, and asexual parasitaemia on the count 
of trophozoites and schizonts against 500 leukocytes, 
assuming an average number of 8000 leukocytes per µl of 
blood.
Criteria for concordance and determination of a final 
result were that after the three reports, results were com-
pared two by two using V, the percentage of concordance: 
V = 2|A − B|/ (A + B) where A represents the parasite 
density reported by reader 1, B reader 2. If, V was < 30%, 
the parasite density was calculated as the geometric 
mean of the two values. If V was > 30%, the third reading 
was used to do the same calculation with A and B. Where 
A + C or B + C the value is less than 30%, the reading was 
validated.
Mosquito membrane feeding assay
A direct mosquito feeding assay procedure (DMFA) pre-
viously described [36], was used to estimate drug effect 
on P. falciparum gametocyte infectivity and mosquito life 
history traits. From each blood sample, approximately 
500  μl of blood in heparinized tubes was distributed to 
each of two membrane feeders and maintained at 37 ℃ 
by circulating water [36]. A mosquito colony of An. gam-
biae was used. The colony was established in 2008 from 
wild-caught gravid females collected in Soumousso 
(40  km southeast of Bobo-Dioulasso) and repeatedly 
replenished with F1 from wild-caught mosquito females 
collected in the same the village. Before the exposure to 
a blood meal, 3–5 days old female mosquitoes were kept 
without sucrose solution for 24  h. For each blood sam-
ple, two cups each containing 40 female mosquitoes were 
placed under the feeders to allow blood feeding through 
parafilm membranes for 30 min. Partially fed and unfed 
mosquitoes were discarded. Fed mosquitoes were kept 
in cages (30 × 30 × 30  cm) in the insectary with con-
stant access to 5% glucose solution on cotton wool pads. 
Among 550 participants from whom blood could be 
collected, blood samples obtained from seven subjects 
could not be used for DMFA for logistics reasons (time 
between blood collection and exposure to mosquitoes 
above 4  h or lack of mosquitoes). On day 7 after mem-
brane feeding, the midguts of mosquitoes of all surviving 
females were dissected and stained with 0.4% mercuro-
chrome in phosphate buffered saline (PBS), pH 7.2. The 
presence and number of oocysts was recorded for each 
mosquito by microscopy. The success of mosquito infec-
tion was estimated by determining both oocyst preva-
lence (proportion of P. falciparum-infected mosquitoes) 
and density of infection (mean number of oocysts among 
infected mosquitoes).
Mosquito life history traits
The effect of SPAQ and AZ on the blood-feeding rate 
and survival was investigated. Because the amount of 
blood ingested can influence the fecundity and sur-
vival of the mosquito, blood meal size was considered 
as a parameter of mosquito life trait. For this pur-
pose, approximately 80 female mosquitoes (2 cups), 
in addition to the mosquitoes dedicated to transmis-
sion assays, were fed to estimate their life history traits 
using blood samples collected from 77 children in the 
three study groups. The fed mosquitoes were placed 
individually in 30-ml drosophila plastic tubes and kept 
in the insectary.
The blood-feeding rate of mosquitoes exposed to 
a blood meal was determined by calculating the ratio 
of fed mosquitoes compared to exposed mosqui-
toes. Mortality among fed mosquitoes was recorded 
every 8  h from the day of membrane blood feeding 
until death of all mosquitoes. Dead mosquitoes were 
removed from their individual tubes. Each tube was 
kept at + 4 ℃ before estimation of blood meal size. The 
size of the blood meal was measured by quantification 
of haematin, a product of digestion of haemoglobin and 
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excreted in faeces of fed mosquitoes. The quantity of 
excreted haematin was estimated by adding 1 ml of 1% 
lithium carbonate (LiCO3) to individual tubes to elute 
faeces and the absorbance of the resulting solution was 
read at 387 nm in a Thermo Scientific Multiskan color-
imeter. A LiCO3 solution was used as a blank. Absorb-
ances were compared with a standard curve made with 
porcine serum haematin to obtain a relative measure of 
blood meal sizes [37].
Statistical analysis
All statistical analyses were performed in R (version 
3.4.0). Logistic regression by generalized linear mixed 
models (GLMM, binomial errors, logit link; lme4 pack-
age) was used to investigate the effect of treatment on: 
(i) asexual parasite prevalence; (ii) gametocyte preva-
lence; (iii) oocyst prevalence, (proportion of dissected 
mosquitoes with at least one oocyst in the midgut); and, 
(iv) mosquito blood-feeding rate. GLMM with negative 
binomial errors (lme4 package, glmer.nb function) [38] 
was used to test the effect of treatment on: (i) asexual 
parasitaemia; (ii) gametocytaemia in participants; and, 
(iii) oocyst density in mosquitoes. Because blood samples 
were not fully independent (some participants were sam-
pled multiple times over time, i.e., pseudo-replication), 
participant identity was included as a random effect in 
all GLMMs. The effect of treatment on the proportion 
of infectious feeds was analysed using a binomial GLM. 
An ANOVA was used to explore the effect of treatment 
on mosquito blood meal size following a log transfor-
mation of haematin concentration. Finally, the effect of 
treatment on mosquito survivorship was analysed using a 
mixed effect Cox’s proportional hazard regression mod-
els (coxme package). Model simplification used step-
wise removal of terms, followed by likelihood ratio tests 
(LRT). Term removals that significantly reduced explana-
tory power (p < 0.05) were retained in the minimal ade-
quate model [39]. Multiple pairwise post-hoc tests were 
performed using the package ‘Multcomp’.
Results
Effect of treatment on the human parasite population
A total of 550 blood collections were obtained from chil-
dren aged 24–59 months. Among them, 373 had received 
chemoprevention (183 SPAQ and 190 SPAQ + AZ) 
(Fig.  1). The average time between drug administration 
and blood collection was similar in the two treatment 
Fig. 1 Summary of the transmission trial. The numbers represent the number of volunteers included at each step. DMFA: Direct membrane feeding 
assay
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groups, with 16.65 and 16.43  days for the SPAQ and 
SPAQ + AZ groups, respectively (W = 15,626, P = 0.35). 
The samples were not fully independent as some partici-
pants were tested more than once; two participants were 
sampled three times and 35 other participants were sam-
pled twice. The proportion of children with slides posi-
tive for asexual stages of Plasmodium sp in the control 
group was 55.9% ± 7% (99/177). Among the 99 positives 
slides, 96 were positive for P. falciparum (97%), includ-
ing 9 co-infections with Plasmodium malariae, 6 with 
Plasmodium ovale and 1 triple infection P. falciparum, 
P. ovale and P. malariae. There were only two mono-
infections of P. malariae and one mono-infection of P. 
ovale. In the SPAQ treatment group, there were 4/183 
(2.19%) slides positive for P. falciparum asexual stages. 
In the SPAQ + AZ treatment group 3/190 (1.58%) slides 
were positive. The treatments SPAQ and SPAQ + AZ sig-
nificantly reduced the prevalence of asexual P. falciparum 
(LRT  X22 = 69, P < 0.0001, Fig. 2A).
There was no difference in P. falciparum asexual preva-
lence between SPAQ and SPAQ + AZ groups (multiple 
pairwise comparison: z = 0.4, P = 0.9). Among infected 
Fig. 2 Effects of SPAQ and SPAQ + AZ on Plasmodium falciparum infection in humans. A The prevalence (± 95% CI) of asexual stage parasitaemia 
for each treatment and the control group. B The density of asexual stage parasites (number of parasites/µl of blood in infected blood collections) 
for each treatment and the control group. Each point represents a blood sample from P. falciparum-positive slides. The horizontal line represents 
the median value of parasite density for each of the three groups, and the upper and lower boundaries of the box indicate the 75th and 25th 
percentile, respectively. Note that the y-axis is on a log10 scale. C The prevalence (± 95% CI) of gametocyte for each treatment and the control 
group as measured by microscopy; D The density of gametocyte (number of gametocytes/µl of blood in gametocyte-positive blood collections) 
for each group. Note that the y-axis is on a  log10 scale. The presence and number of asexual stages or gametocytes in samples was determined by 
microscopic observation. Different lowercase letters above the bars denote statistically significant differences based on multiple pair-wise post-hoc 
tests. NS: Not significant
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children in the control group, the mean P. falciparum 
asexual parasite density was 16,074 ± 2803 parasites/
µl (range: 28–128,800). The four infected individuals 
of the SPAQ group had a mean asexual parasitaemia of 
3548 ± 3167 parasites/µl (range: 36–13,022) and among 
the three positive children from the SPAQ + AZ group 
the mean density was 10,709 ± 7310 parasites/µl (range: 
1560–25,160). Asexual parasite density was not signifi-
cantly different among the three groups (LRT  X22 = 2.27, 
P = 0.32; Fig. 2B).
Chemoprevention with SPAQ or SPAQ + AZ treat-
ments, significantly reduced the P. falciparum gameto-
cyte prevalence (LRT  X22 = 54, P < 0.0001). There were 
3/183 (1.6%) gametocyte-positive slides in the SPAQ 
group and 9/190 (4.7%) in the SPAQ + AZ group com-
pared to a prevalence in the control group of 27% ± 6.5 
(48/177). There was no difference in gametocyte preva-
lence between SPAQ and SPAQ + AZ groups (multiple 
pairwise comparison: z = 1.6, P = 0.2). The mean number 
Fig. 3 Effects of SPAQ and SPAQ + AZ on Plasmodium falciparum infectivity from humans to mosquitoes. A The proportion (± 95% CI) of feeds 
resulting in at least one successful mosquito infection (i.e., a minimum of one mosquito harbouring a minimum of one oocyst) for each treatment 
group. There were 171 feeds for the control, 182 for SPAQ and 190 for the SPAQ-AZ treatment and an average of 38.87 ± 0.48 (median = 41, 
range = 5–51) mosquitoes were dissected per feed (n total = 21,108 mosquitoes). B Oocyst prevalence (± 95% CI) defined as the total number 
of mosquitoes fed with blood drawn from each study group harbouring at least one oocyst in their midgut out of the number of dissected 
mosquitoes from this group. C Oocyst density defined as the number of oocysts observed in infected mosquitoes for each group. The horizontal 
line represents the median value of density for each of the three study groups, and the upper and lower boundaries of the box indicate the 75th 
and 25th percentile, respectively. D Oocyst density following infectious feeds on samples from the control group, SPAQ group and SPAQ + AZ 
group. Note that the y-axis on panels (C) and (D) is on a  log10 scale. Different lowercase letters above the bars denote statistically significant 
differences based on multiple pair-wise post-hoc tests. NS: Not significant
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of gametocytes/µl of blood was not influenced by the 
treatments (LRT  X22 = 0.73, P = 0.69; Fig. 2D).
Effect of treatment on malaria transmission from humans 
to mosquitoes
A total of 21.108 mosquitoes, fed with one of 543 blood 
samples (171 from the control group, 182 from the 
SPAQ treatment group. and 190 from the SPAQ + AZ 
treatment group) through direct membrane feeding 
assays, were dissected seven days post feeding. Mos-
quitoes were successfully infected from a total of 88 
blood samples (55 feeds from the control group, 10 
feeds from the SPAQ treatment group and 23 from 
the SPAQ + AZ treatment group). The proportion of 
feeds giving a successful mosquito infection varied sig-
nificantly among the groups (LRT  X22 = 61, P < 0.0001; 
Fig.  3A). Thirty-two per cent (55/171) of the blood 
feeds originating from the control group resulted in 
successful mosquito infection. The proportion of infec-
tious feeds from the SPAQ + AZ group (23/190) was 
twice as large as that from the SPAQ group (10/182) 
(LRT  X21 = 5.2, P = 0.02, multiple pair wise comparison: 
z = 2.2, P = 0.07, Fig. 3A), suggesting a significant effect 
of AZ on gametocyte infectivity.
The prevalence of oocysts (i.e., the number of mosqui-
toes presenting at least one oocyst in the midgut out of 
the total number of dissected mosquitoes) was higher 
in the control group than in the two treatment groups 
Fig. 4 Effect of SPAQ and SPAQ + AZ on mosquito life history traits. A Mosquito blood-feeding rate, expressed as the proportion (+ 95% CI) of 
engorged mosquitoes out of the total number exposed to the blood meal; B Mosquito blood-meal size, expressed as the quantity of haematin 
in µg excreted by individual mosquitoes. Note that the y-axis is on a  log10 scale. C The daily survival of mosquitoes individually kept in drosophila 
tubes. D The relationship between mosquito lifespan and blood meal size. Note that the x-axis is on a  log10 scale
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(X22 = 22.8, P < 0.001, Fig.  3B). Following 55 infectious 
feeds on sample from the control group, including 25 
from gametocyte-positive blood samples (19 for P. falci-
parum, 1 for P. ovale, 1 for P. malariae, 3 mixed infections 
with P. falciparum and P. malariae and 1 with P. falcipa-
rum, P. ovale and P. malariae), 380 out of 6,349 dissected 
mosquitoes (6%), were infected (Fig.  3B). In the SPAQ 
group, 21 out of 7,207 mosquitoes (0.29%) were infected 
from 10 infectious feeds, including one from a P. falci-
parum gametocyte-positive blood collection (Fig.  3B). 
In the SPAQ + AZ group, 63 out of 7,552 mosquitoes 
(0.8%) were infected from 23 infectious feeds, including 
3 from P. falciparum gametocyte-positive blood samples 
(Fig.  3B). There was no difference in oocyst prevalence 
between SPAQ and SPAQ + AZ groups (multiple pair 
wise comparison: z = 1.3, P = 0.4).
Although mosquitoes infected from blood samples 
obtained from the SPAQ + AZ group harboured rela-
tively more oocysts in their midguts (mean ± se density 
of 43 ± 7) compared to mosquitoes infected from samples 
obtained from the control (10.9 ± 1.2) or SPAQ (1.8 ± 0.3) 
groups, the difference was not statistically significant 
(LRT X22 = 4.4, P = 0.11, Fig.  3C). This is because more 
than half of the mosquito infections in the SPAQ + AZ 
group (34/63) came from a single gametocyte carrier. Fig-
ure 3D shows the oocyst density produced by each infec-
tious feed (n = 55 for the control group, 10 for SPAQ and 
23 for SPAQ + AZ). Most infectious feeds from the SPAQ 
or SPAQ + AZ group resulted in single infected mosqui-
toes harbouring very few oocysts (Fig. 3D).
Effect of treatment on mosquito blood‑feeding success, 
mosquito blood‑meal size and on mosquito survival
To investigate the effect of treatment on mosquito 
blood-feeding success, the proportion of fully engorged 
females was recorded for 34 feeds on blood samples from 
the control group (2547 mosquitoes), 19 feeds from the 
SPAQ group (1,491 mosquitoes) or 21 feeds from the 
SPAQ + AZ group (1647 mosquitoes). A marginally sig-
nificant effect of treatment on mosquito feeding rate was 
observed (LRTX22 = 6.0, P = 0.048, Fig. 4A), with slightly 
lower feeding success with blood samples from the con-
trol group.
To investigate the effect of treatment on mosquito 
blood-meal size and mosquito survival, fully fed females 
from 35 feeds on blood samples from the controls group 
(1440 mosquitoes), 21 feeds from the SPAQ group (947 
mosquitoes) or 21 feeds from the SPAQ + AZ group 
(1,055 mosquitoes) were kept individually in drosophila 
plastic tubes. The size of the blood meal was measured 
following the haematin dosage procedure. There was no 
effect of SPAQ or SPAQ + AZ on mosquito blood meal 
size (LRT  X22 = 3.0, P = 0.12, Fig. 4B).
The daily mortality of individual female mosquitoes was 
recorded. There was a slight but statistically significant 
negative effect of SPAQ and SPAQ + AZ on mosquito 
survival compared to mosquitoes fed with blood samples 
from the control group (median longevity of mosquitoes 
10, 9 and 9  days for the control, SPAQ and SPAQ + AZ 
groups, respectively,  LRTX22 = 330, P < 0.0001, Fig.  4C, 
Table  1, multiple pair-wise comparisons, control-SPAQ: 
z = 3.338, P = 0.002, control-SPAQ + AZ: z = 2.462, 
P = 0.036, SPAQ-SPAQ + AZ: z = 0.8, P = 0.7).
There was a significant positive relationship between 
mosquito lifespan and blood meal size (LRT X21 = 142, 
P < 0.001, Fig.  4D), with females that took large blood 
meals living longer than those that took smaller blood 
meals. This relationship was true for all three groups 
(treatment by blood meal size interaction: LRT X22 = 1.5, 
P = 0.17, Fig. 4D).
Discussion
The present study investigated the effect of SMC with or 
without the addition of AZ on transmission of malaria. 
A significant reduction in malaria prevalence was found 
among blood samples obtained from treated children 
(SPAQ or SPAQ + AZ) compared to samples from the 
control group but no significant difference was seen 
between the SPAQ and SPAQ + AZ groups. This find-
ing indicates that addition of AZ does not influence the 
malaria prevalence in the context of SMC as previously 
observed [4]. Consistently, the prevalence of gametocytes 
was significantly lower in children treated with SPAQ or 
SPAQ + AZ than in the controls but there was no differ-
ence between SPAQ and SPAQ + AZ groups. These find-
ings indicate that SMC with SPAQ may have an effect on 
the overall transmission of malaria, especially if SMC was 
extended to older children, but that addition of AZ will 
not enhance this effect.
The proportion of mosquitoes infected from blood 
samples obtained from children in the control group was 
significantly higher than that in mosquitoes fed on blood 
from children in the SPAQ or SPAQ + AZ groups. The 
low rate of infectivity of post-treatment patients may be 
Table 1 Risk of mortality (hazard ratio) along with the standard 
error, z and P-value for each treatment group relative to the 
control group
Treatment Hazard ratio (se) z P‑value
SPAQ 1.486 (0.119) 3.34 0.0008
SPAQ + AZ 1.333 (0.117) 2.46 0.014
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due to the cumulative effects of the treatment; that the 
sporontocidal activity of SP is known to affect parasite 
development prior to the stage of mature oocyst when SP 
is ingested together with gametocytes during the mos-
quito blood meal [12, 36] and the rapid action of AQ on 
asexual forms that limits the presence and number of 
asexual parasites that engage in the gametocytogenesis 
[15, 40, 41].
A higher proportion of mosquitoes fed on blood sam-
ples from children in the SPAQ + AZ group were infec-
tious compared to feeds on samples from children in the 
SPAQ group suggesting that mosquitoes could be more 
prone to become infected with Plasmodium when feed-
ing on blood containing AZ. Two hypotheses may explain 
the present result. Firstly, despite the relatively short half-
life of AZ (44  h) [42], AZ remains detectable for more 
than 20  days, especially in white blood cells [43] and 
AZ ingested by mosquitoes during blood feeding may 
increase mosquito permissiveness to malaria infection 
by affecting their midgut microbiota and subsequently 
impact on microbe-parasite interactions, as previously 
observed with other antibiotics [19, 27]. However, this 
contrasts with previous findings, which showed that AZ 
added to an infectious blood meal reduced the parasite 
load in mosquitoes [28]. Dose-dependent effects of anti-
biotics on malaria transmission could account for these 
different findings. Secondly, mechanisms occurring in the 
human host could explain the influence of AZ on infec-
tivity of gametocytes to mosquitoes. Because gameto-
cyte density in infected individuals is often too low to be 
detected by standard light microscopy [44, 45], it cannot 
be excluded that the AZ treatment increases the preva-
lence of gametocyte carriage and subsequently increases 
transmission despite low densities of sexual parasites. 
Molecular detection and quantification of gametocytes 
may help understanding the effect of AZ administration 
on malaria transmission.
A marginal effect of the treatment with SPAQ or 
SPAQ + AZ on the mosquito feeding rate was observed. 
Mosquitoes seemed to be more prone to complete a 
blood meal when blood was collected from children who 
had received treatment compared to controls. This sug-
gests that SPAQ or SPAQ + AZ influence mosquitoes 
feeding behaviour, increasing appetite. This may be due 
to the presence of drug metabolites still present in the 
blood. Indeed, it has been demonstrated that several 
chemical families may influence the attraction and feed-
ing behaviour of the vector mosquitoes [46].
Transmission of Plasmodium is closely dependent on 
the ability of the mosquito to harbour the parasite and to 
survive long enough for them to develop. The probability 
of mosquito survival was significantly lower in the treated 
groups (SPAQ, SPAQ + AZ) than in the control group, 
with a median longevity one day shorter, suggesting that 
the drugs reduced mosquito survival in accordance with 
previous observations [17, 28]. Although the observed 
reduction of survival is moderate in this study, probably 
due to low concentrations of drugs in blood collected 14 
to 21 days post treatment, the reduction of mosquito life 
span could significantly disturb the Plasmodium sporo-
gonic cycle. Indeed, a decreased mosquito survival rate 
strongly affects vectorial capacity, by decreasing the like-
lihood of infected mosquitoes surviving beyond the para-
site extrinsic incubation period (time required between 
being ingested and becoming infective to humans), and 
therefore the probability of transmitting the disease to 
new hosts [47].
The moderate lethal effect of the molecules on the mos-
quito feeding rate and on mosquito longevity would have 
been more significant if the blood had been drawn in at 
an interval of time less than 14  days when the concen-
tration of the molecules is higher in the blood. Therefore, 
subsequent studies could be carried out by taking blood 
at different times points after the treatment to deter-
mine the relation between the time of chemoprevention 
administration and it effect on mosquito fitness and par-
asite transmission.
Conclusion
This study, conducted in Burkina Faso, showed that 
SMC greatly reduces the infectious parasite reservoir, 
decreases gametocyte carriage and infectivity to mos-
quitoes. The finding indicates that the addition of AZ to 
SPAQ prophylaxis slightly influences human to mosquito 
malaria transmission, with an increased proportion of 
infectious mosquito feeds 2 to 3 weeks after the start of 
treatment in children with AZ or SPAQ. Despite the fact 
that this effect was marginal and could be due to chance, 
this is a potentially undesirable effect of adding AZ to 
SMC and does not support mass administration of this 
antibiotic in the context of malaria transmission.
The result also showed that SMC using SPAQ, with 
or without AZ, affects the mosquito’s life traits with a 
slightly enhanced blood feeding success and a decrease 
in mosquito survival rate. The importance of mos-
quito longevity in malaria transmission suggests that, 
between these two effects on mosquito’s life traits, the 
effect on survival may be the most important in terms 
of vectorial capacity. This suggests that in addition to 
the prophylactic effect in humans and the reduction of 
transmission to mosquitoes, SMC may also affect mos-
quito longevity in a way that confirms its value in the 
fight against malaria.
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The findings show a strong benefit of SMC in reduc-
ing human to mosquito transmission. However, 
although the effect was only moderate, the results 
show that the addition of AZ to SPAQ in SMC might 
favour malaria transmission and does not support mass 
administration of this drug in the context of malaria 
control.
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